Shreveport, LA — Dr. Reddy’s Laboratories, Inc. USA, an India-based pharmaceutical manufacturer, has announced the closure of its Shreveport facility, resulting in the layoff of 107 employees. The company has notified employees that the layoffs, expected to be permanent, will occur over a two-week period beginning March 14, 2025.
The decision comes as Dr. Reddy’s Laboratories disclosed in a recent Securities and Exchange Commission (SEC) filing that it is selling the Shreveport subsidiary and manufacturing plant to Jaguar Labs Holdings, a Delaware-based limited liability company. The company described the facility as “nonstrategic” with no pipeline of future products, prompting the sale.
The Shreveport site holds significance in the pharmaceutical industry as the nation’s largest producer of silver sulfadiazine cream, a topical treatment for burns, and the second-largest producer of prescription ibuprofen for the North American market.
Dr. Reddy’s acquired the plant in 2008 from BASF, which had used the facility to manufacture ibuprofen, burn creams, and gout medications. Despite its history of production and market contribution, the plant has been deemed no longer essential to Dr. Reddy’s strategic direction.
The closure of the Shreveport facility marks a notable shift in the company’s operations and leaves uncertainty for the future of its 107 affected employees. Jaguar Labs Holdings’ plans for the plant remain unclear.
For now, the pharmaceutical sector in Shreveport will face a significant loss as one of its key facilities ceases operations. Further developments regarding the plant’s sale and the impact on the community are expected in the coming months.